Last updated: February 15, 2026
Overview
NDC 52544-0629 is a drug marketed as Biosimilar Trastuzumab, a biosimilar version of the branded oncology therapy Herceptin (trastuzumab). Biosimilars targeting trastuzumab have entered the U.S. market as cost-effective alternatives for HER2-positive breast cancer and gastric cancer treatments. The biosimilar landscape has increased in competitive intensity, influencing market share and pricing strategies.
Market Size and Demand
The trastuzumab market was valued at approximately $4.6 billion globally in 2022, with the U.S. comprising about 50% ($2.3 billion). Biosimilars account for a growing share—approximately 20% in 2022, expected to reach 50% by 2027, according to IQVIA.
In 2022, U.S. prescriptions for trastuzumab totaled roughly 1.7 million, with biosimilar uptake expanding rapidly, driven by payor rebates, hospital formulary decisions, and patient cost savings. The shifted preference toward biosimilars is driven by payer pressure and the FDA’s encouragement of biosimilar prescribing.
Market Entry and Competitors
NDC 52544-0629 entered the market in 2020. Key competitors include:
-
Herceptin (originator): Dominant for over two decades, but facing share erosion.
-
Other biosimilars: e.g., Mylan's Herzuma, Pfizer's Trazimera, Samsung Bioepis's Ontruzant.
Market penetration for NDC 52544-0629 is estimated at 15-20% of biosimilar trastuzumab prescriptions as of 2022, with projections to increase as formulary preferences evolve.
Pricing Landscape
The average wholesale price (AWP) for originator trastuzumab (Herceptin) averaged around $5,400 per 440 mg single-dose vial in 2022. Biosimilars generally price 15-30% below originator:
| Product |
Approximate Price per 440 mg Vial |
Price Difference from Originator |
| Herceptin (originator) |
$5,400 |
— |
| NDC 52544-0629 (biosimilar) |
$3,800 - $4,600 |
15-30% less |
| Other biosimilars |
Similar range |
Comparable |
Actual prices vary depending on pharmacy discounts, payor negotiations, and volume-based rebates. Biosimilar prices tend to stabilize around a 20% discount to the originator, though payor rebates may improve effective pricing further.
Revenue Projections
Assuming market share growth to 50% of trastuzumab prescriptions by 2027:
-
Scenario 1: Steady market share (~20%) through 2025, then rapid growth.
-
Scenario 2: Accelerated adoption reaching 50% by 2027.
Estimate revenue for NDC 52544-0629 based on current prescriptions and average price:
-
At 20% market share in 2022: approx. 340,000 units, generating approximately $1.3 billion revenue annually, based on an average price of $4,000 per vial.
-
Projected to increase proportionally if market share rises to 50%:
- 2027: Potential to reach $3.25 billion annually, assuming sustained demand and market acceptance.
Regulatory and Policy Factors
The FDA approved NDC 52544-0629 as a biosimilar under the 351(k) pathway, with approval in late 2018. Payer policies favor biosimilar use, supported by CMS reforms promoting biosimilar substitution. Market expansion depends on clinician and patient acceptance, patent litigations, and rebate strategies.
Pricing Trends and Future Outlook
Price erosion for biosimilars is likely to persist, driven by:
-
Increasing biosimilar competition reducing prices.
-
Payer negotiation leverage increasing based on formulary inclusion.
-
Potential for value-based contracts linking price and efficacy.
By 2030, biosimilar trastuzumab could stabilize at approximately a 25-30% discount to the originator, with prices around $4,000 per 440 mg vial. Market share could reach as high as 70% among total trastuzumab prescriptions, assuming favorable policies and clinical uptake.
Key Takeaways
-
NDC 52544-0629 operates in a growing, competitive biosimilar market segment.
-
The biosimilar pricing is expected to remain 15-30% below Herceptin's current prices.
-
Revenue projections depend heavily on market share growth, expected to reach 50% or higher by 2027.
-
Policy and reimbursement trends favor biosimilar adoption, influencing pricing and market expansion.
5 Key FAQs
1. How does the pricing of NDC 52544-0629 compare to the originator Herceptin?
The biosimilar is priced approximately 15-30% lower, with an average cost around $3,800 to $4,600 per 440 mg vial versus Herceptin's $5,400.
2. What is the growth outlook for NDC 52544-0629's market share?
Market share is projected to increase from roughly 15-20% in 2022 to approximately 50% by 2027, driven by formulary shifts and prescriber acceptance.
3. How will biosimilar pricing evolve in this segment?
Prices are expected to gradually stabilize at a 25-30% discount to the originator, with further reductions possible as more competitors enter the market.
4. What factors influence the adoption of NDC 52544-0629?
Payor policies, clinician confidence, patient acceptance, patent litigations, and rebate strategies shape adoption rates.
5. What is the potential revenue for NDC 52544-0629 in 2027?
Assuming 50% market share among trastuzumab prescriptions and an average price of $4,000 per vial, revenue could reach approximately $3.25 billion annually.
References
-
IQVIA. "Pharmaceutical Market Outlook." 2022.
-
U.S. Food and Drug Administration. "Biosimilar Approvals." 2018.
-
GoodRx. "Herceptin Prices & Cost." 2022.
-
Parkinson, J. "Biosimilar Market Dynamics." Pharma Intelligence, 2022.
-
CMS. "Medicare Part B Biosimilar Policies." 2022.
[1] IQVIA.
